Novocure has announced promising Phase 3 PANOVA-3 trial results for its Tumor Treating Fields (TTFields) therapy, showing improved outcomes for patients with unresectable, locally advanced pancreatic cancer.
Key Results:
- Median overall survival (mOS):
- TTFields + standard therapy: 16.2 months
- Standard therapy alone: 14.2 months
- → Statistically significant 2-month improvement
- 1-year survival rate:
- TTFields arm: 68.1%
- Control arm: 60.2%
- Median pain-free survival:
- TTFields: 15.2 months
- Control: 9.1 months
- Safety: Well tolerated with no new safety signals; most common side effect was moderate skin irritation.
Presented at the ASCO 2025 Annual Meeting and published in the Journal of Clinical Oncology, these results underscore TTFields’ ability to extend life and reduce pain—a key clinical challenge in pancreatic cancer.
Novocure plans to submit the data to the FDA for premarket approval in the second half of 2025.
Follow MEDWIRE.AI for the latest on cancer treatment innovations.
